NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia

Imatinib resistance in chronic myelogenous leukemia (CML) is a clinical problem. The present study examined the role of N-Myc downstream regulatory gene 3 (NDRG3) in imatinib resistance in CML. Quantitative PCR demonstrated that NDRG3 was highly expressed in patients with CML. Cell Counting Kit (CCK...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiao, Rong, Simin, Sun, Yunxiao, Yin, Baohui, Yang, Xiancong, Lu, Xiaoqing, Sun, Hongfang, Yan, Yunfei, Sun, Guangbin, Liang, Yan, Wang, Pingyu, Xie, Shuyang, Li, Youjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308491/
https://www.ncbi.nlm.nih.gov/pubmed/37350410
http://dx.doi.org/10.3892/or.2023.8589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308491/
https://www.ncbi.nlm.nih.gov/pubmed/37350410
http://dx.doi.org/10.3892/or.2023.8589

Ejemplares similares